Takeda Poised For Acquisitions?

In a possible change to its core growth strategy, leading Japanese drugmaker Takeda could be poised to make another large acquisition. The company - which has estimated cash reserves of more than US$14bn - has traditionally favoured intensive product development as its main engine for revenue growth. However, a weak R&D pipeline and slowness to embrace the potential of biotech may have prompted company officials to work on 'a number of deals' to expand inorganically. This could bolster the company's value while pipelines

To read the full article, please choose one of the following options: